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Abstract
Damaged cardiac valves attract blood-borne bacteria, and infective endocarditis is often caused by viridans group
streptococci. While such bacteria use multiple adhesins to maintain their normal oral commensal state, recognition of
platelet sialoglycans provides an intermediary for binding to damaged valvular endocardium. We use a customized
sialoglycan microarray to explore the varied binding properties of phylogenetically related serine-rich repeat adhesins, the
GspB, Hsa, and SrpA homologs from Streptococcus gordonii and Streptococcus sanguinis species, which belong to a highly
conserved family of glycoproteins that contribute to virulence for a broad range of Gram-positive pathogens. Binding
profiles of recombinant soluble homologs containing novel sialic acid-recognizing Siglec-like domains correlate well with
binding of corresponding whole bacteria to arrays. These bacteria show multiple modes of glycan, protein, or divalent
cation-dependent binding to synthetic glycoconjugates and isolated glycoproteins in vitro. However, endogenous
asialoglycan-recognizing clearance receptors are known to ensure that only fully sialylated glycans dominate in the
endovascular system, wherein we find these particular streptococci become primarily dependent on their Siglec-like
adhesins for glycan-mediated recognition events. Remarkably, despite an excess of alternate sialoglycan ligands in cellular
and soluble blood components, these adhesins selectively target intact bacteria to sialylated ligands on platelets, within
human whole blood. These preferred interactions are inhibited by corresponding recombinant soluble adhesins, which also
preferentially recognize platelets. Our data indicate that circulating platelets may act as inadvertent Trojan horse carriers of
oral streptococci to the site of damaged endocardium, and provide an explanation why it is that among innumerable
microbes that gain occasional access to the bloodstream, certain viridans group streptococci have a selective advantage in
colonizing damaged cardiac valves and cause infective endocarditis.
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Introduction
Infective endocarditis (IE) remains a disease with considerable
morbidity and mortality [1,2]. Of the numerous bacteria that have
the opportunity to enter the bloodstream, three major genera of
Gram-positive pathogens (streptococci, staphylococci and entero-
cocci) dominate in IE. Streptococci and staphylococci account for
80% of IE cases [3], and viridans group streptococci, including
Streptococcus gordonii and Streptococcus sanguinis, make up to
half of such cases [4]. Unlike the intrinsically virulent staphylo-
cocci, streptococci causing IE are commensal species that normally
reside in the oral cavity and show relatively weak or no
pathogenicity. However, they have the potential to cause life-
threatening IE when they enter the bloodstream through lesions in
the oral epithelia or after dental procedures [5]. The question
arises as to why these particular organisms have such a selective
advantage in causing IE. Answers to this question are of
importance in preventing and treating this serious disease.
The pathogenesis of IE is complex but bacterial adherence to
damaged heart valves is a required event [1,6]. Platelets appear to
play a crucial role in pathogenesis, as the streptococci associated
with IE can bind to platelet components to initiate adherence to
damaged human heart valves [7]. Several streptococcal adhesins
are known to bind human platelets [8–15]. Among the best
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characterized are GspB and Hsa of S. gordonii and SrpA of S.
sanguinis, all belonging to a conserved family of serine-rich repeat
(SRR) glycoproteins [13–15]. The SRR glycoproteins and
corresponding specialized secretion systems are being defined in
a growing number of pathogens, indicating their important roles in
the behavior of Gram-positive organisms [16,17]. However, we
are only beginning to understand the functions of this interesting
family of proteins.
All human cell surfaces are covered by a dense and complex
layer of glycans [18–20]. Glycan-mediated host-pathogen interac-
tions are involved in various human disease processes [21]. Sialic
acids (Sias) are a diverse group of a-keto acids with a shared nine-
carbon backbone [22,23]. Given their presence at terminal
positions of cell surface and secreted glycoconjugates, they mediate
or modulate various biological interactions [24,25]. Interestingly,
GspB, Hsa and SrpA are all Sia-binding adhesins. GspB, the SRR
adhesin from S. gordonii strain M99, was recently found to
contain a subdomain in its binding region (BR) [26], with the
topology and strand inserts similar to the V-set Ig-like fold adopted
by mammalian sialic acid binding immunoglobulin-like lectins
(Siglecs) [27]. Each of the other two homologous SRR adhesins,
Hsa from S. gordonii strain DL1 and SrpA from S. sanguinis
strain SK36, also contains a Siglec-like subdomain in their BRs
[26].
Taken together, existing data suggests that the Sia-binding
capabilities of GspB, Hsa and SrpA are conferred by their Siglec-
like modules, and that such binding assists interactions with
platelets. This surface property may help targeting the bacteria to
the coagulum made of platelets and other components on
damaged cardiac valves and act as a contributory factor in the
pathogenesis of IE. However, detailed characterization of cognate
ligands of such adhesins is lacking. It is also not known whether
these bacteria could selectively target platelets in fluid human
whole blood, a process that is under-explored but may contribute
to the pathogenesis of IE [1]. This question is of particular interest
also because the endovascular system is an environment where
numerous potential sialoglycan competitors exist [28]. Such
selectivity would thus play an essential role for the successful
delivery and adhesion of bacteria to damaged valvular endocar-
dium, and provide an explanation to the selective advantage of
certain types of bacteria in causing IE.
Here we utilize a number of complementary techniques and
novel assays to study the role of the Siglec-like domain-containing
SRR-adhesins in bacterial recognition of host sialoglycans. We
explore mechanisms of these bacterial interactions with saliva and
in whole blood. Our finding extends previous understanding of the
mechanisms of infective endocarditis. The novel insights gained
help us to better understand the contribution of Sia-binding
adhesins in the pathogenesis of IE. In particular, we address
questions including the following: 1) What are the detailed
sialoglycan-binding characteristics of GspB-BR, Hsa-BR, and
SrpA-BR?; 2) Are the Siglec-like BRs of these adhesins responsible
for whole bacterial recognition of sialoglycans?; 3) Are Siglec-like
domain-containing SRR adhesins common among oral strepto-
cocci, and is there a good phylogeny-function relationship?; 4)
How do these oral streptococci interact with saliva from the oral
cavity, and with blood components from the bloodstream?; and 5)
Can these bacteria preferentially recognize platelets in the setting
of whole human blood via Sia-adhesin interactions, despite
numerous potential sialoglycoprotein competitors from plasma
and surfaces of other blood cells?
In addressing the last issue, we have developed a novel whole
blood-whole bacterium flow cytometry assay that is most relevant
to bona fide human conditions. For the first time, we have
demonstrated that oral streptococci can indeed selectively target
platelets in human whole blood. It appears that circulating
platelets may act as inadvertent Trojan horse carriers of oral
streptococci to the site of damaged endocardium. By serendipity,
certain sialoglycan-binding properties that facilitate normal oral
commensalism seem to have set these bacteria up to be
inadvertent, yet highly specific causative agents of endocarditis,
via platelet intermediaries. As a proof of concept, we have also
shown that soluble recombinant bacterial adhesin binding region
proteins can block the preferred platelet-bacterial interactions in
whole blood. The knowledge gained may contribute to the
development of novel preventive or therapeutic approaches
against infective endocarditis.
Results
Glycan microarray analyses show varied Sia-binding
specificities of streptococcal adhesins containing a
Siglec-like domain
Glutathione S-transferase (GST)-tagged BRs of GspB, Hsa,
and SrpA (see Table S1 for details), were tested for binding to
various sialoglycans, using a recently developed slide micro-
array. This unique sialoglycan microarray presents over 70
synthetically recreated naturally-occurring oligosaccharide struc-
tures with diverse sialic acid forms, glycosidic linkages, and
underlying glycans, representing the broadest range of such
targets available to date [23,29]. All three proteins exclusively
bound to glycans terminated with sialic acids but not non-
sialylated ones (Figure 1A–1D). However, they also showed
distinct specificities.
GspB-BR interacted with a very narrow spectrum of sialogly-
cans, primarily Neu5Aca2-3Galb1-3GalNAca1- (Glycan #15, the
sialyl T antigen, sTa) and related structures (Figure 1A and 1D). 9-
O-Acetylation of the Neu5Ac moiety of sTa (Glycan #9,
compared to #15) did not influence binding significantly.
Sulfation of underlying glycans also showed no effect (Glycans
Author Summary
Bacterial infective endocarditis remains a disease with
considerable morbidity and mortality. Of the numerous
bacteria that can enter the bloodstream, certain oral
commensal viridans group streptococci are among the
major causative organisms of endocarditis. However,
mechanisms underlying this selectivity are incompletely
understood. Interactions between adhesins of such bacte-
ria and human platelet sialoglycans are believed to play an
important role in this selectivity, by facilitating bacterial
adherence to damaged heart valves. Nevertheless, the
molecular requirements for these interactions are not fully
explored. Particularly, it is unclear whether selective
targeting of platelets by these bacteria actually occurs in
fluid human whole blood, an environment where numer-
ous potential sialoglycan competitors exist. In the present
work, we have addressed these important issues. We
characterize in detail the glycan-binding spectra of a series
of serine-rich repeat adhesins of oral streptococci. For the
first time, we demonstrate that oral streptococci can
indeed selectively target platelets in whole human blood.
As a proof of concept, we also show that soluble
recombinant bacterial adhesin binding region proteins
can block the preferred platelet-bacterial interactions in
whole blood. The knowledge gained from this study may
help the development of novel preventive or therapeutic
approaches against infective endocarditis.
Oral Streptococci Target Platelets in Fluid Human Whole Blood
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#57, 58 and 62, 63, compared to #55, 56, and 11, 12,
respectively). In contrast, Hsa-BR bound a broad range of Sias
with different underlying glycans (Figure 1B and 1D). Conspicu-
ously, it recognized all a2-3-linked Sias but not any a2-6- or a2-8-
linked ones. This finding expands on previous studies, which
showed that Hsa could bind a2-3-linked Sias with three different
underlying glycans, specifically, sTa, Neu5Aca2-3Galb1-
4GlcNAcb1- (39SLn) and Neu5Aca2-3Galb1-4Glcb1- (39SL)
structures [30,31]. Our microarray displays Sias with over 10
different underlying glycans (Table S2), and it appears that every
a2-3-linked Sia present on the array could be bound by Hsa-BR
(Glycans #1, 2, 7-16, 21, 22, 25, 26, 29, 30, 33-36, 39, 40, 55-58,
and 60-63) (Figure 1B and 1D). Similar to GspB-BR, 9-O-
acetylation on Sia did not block Hsa-BR binding. In contrast to
GspB-BR, Hsa-BR could not only recognize tri- and oligo-
saccharide Sias, but also di-saccharide Sias (Glycans #25, 26, 29,
30). Sulfation significantly increased binding (Glycans#57, 58 and
62, 63, compared to #55, 56, and 11, 12, respectively). Notably,
SrpA-BR recognized sialoglycans in a manner resembling Hsa-BR
more than GspB-BR (Figure 1C), showing binding to both di-
saccharide and tri-/oligo-saccharide Sias. Sulfation also increased
binding. Moreover, we tested the maltose-binding protein (MBP)
Figure 1. Sialoglycan microarray analysis of binding specificities of adhesin-BRs and corresponding whole bacteria. (A–C) Binding of
the adhesin-BR proteins at 50 nM is presented. (n = 4, SD). (D) Adhesin-BR proteins and Cy3-labeled whole bacteria were assayed using the same
sialoglycan microarrays. Heat map was generated using the method as previously described [29]. R1 and R2 represent two different spacers.
doi:10.1371/journal.ppat.1004540.g001
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-tagged Hsa-BR, which showed the same binding characteristics as
GST-tagged Hsa-BR (Figure S1), indicating that tagging methods
did not alter adhesin binding.
Whole bacteria bind to glycan microarrays in patterns
similar to those of their adhesin-BR fusion proteins
To test whether the SRR adhesin-BR fusion proteins faithfully
represent the binding properties of the corresponding whole
organisms, we assessed direct binding of strains M99, DL1, and
SK36 to the same microarray. To confirm that binding was due to
expression of the adhesin, we also tested isogenic variants of each
strain, in which the gene encoding the SRR glycoprotein had been
deleted (M99DgspB, DL1Dhsa, and SK36DsrpA). Prior glycan
microarray studies using whole bacteria were characterized by high
background noise or no success at all (http://www.functional
glycomics.org/glycomics/publicdata/selectedScreens.jsp). However,
our current efforts at optimization yielded good signal-to-noise ratios
(Figure S2). Notably, DL1 and M99 showed nearly identical binding
profiles as their respective adhesins, Hsa and GspB, on the array
(Figure 1D). In keeping with the relatively low binding of SrpA to the
arrayed Sias (see mean relative fluorescence intensities in Figure 1A–
1C), the corresponding bacteria SK36 showed minimal binding.
Importantly, all adhesin-deficient mutant strains showed no binding
to the sialosides on the microarrays. Thus, whole bacterial binding to
the immobilized sialoglycans was SRR adhesin-dependent.
Phylogeny of binding regions of Siglec-like
domain-containing adhesins from selected strains
corroborates binding result
The SRR glycoproteins comprise a large family of adhesins in
Gram-positive bacteria [16]. To determine the prevalence of
Siglec-like domain-containing adhesins in the family, we searched
public databases and gathered additional sequence data from our
lab collection (strains PS478, 72-40, and G9B). Seventeen
additional predicted SRR homologs of GspB, Hsa, and SrpA
were identified based on their Siglec-like domain-containing BR
sequences (Figure 2A). While GspB clustered with five other SRR
proteins, Hsa and SrpA appeared in a different branch, and were
more closely related to each other than to GspB. The phylogenetic
relationship agreed with their functional relationships in terms of
ligand repertoire (Figure 1A–1C). To further demonstrate this
phylogeny-function relationship, we produced additional GST-
tagged adhesin-BR proteins (GspBPS478BR, GspB72-40BR, and
GspBG9BBR), which differ from GspBM99BR by only a few amino
acid residues (Figure S3). We then labeled the corresponding
whole bacteria (strains PS478, 72-40, and G9B), and tested the
organisms together with their adhesin-BRs on the same sialoglycan
microarray. The new adhesin-BRs displayed binding properties
that were nearly identical to those of GspBM99BR (Figure S4). The
strains also showed binding patterns nearly identical to that of
their adhesins, as well as to strain M99, whereas an adhesin-
deficient mutant of 72-40 (PS1070) [32] showed no binding to any
sialoglycan. Moreover, the glycan-binding properties of all above-
mentioned adhesin-BR fusion proteins were confirmed by a
conventional enzyme-linked lectin assay [26], using two model
glycans, sTa and 39SLn (Figure 2B and 2C).
Taken together, the data show that the Siglec-like domain-
containing bacterial adhesins are prevalent in S. gordonii and S.
sanguinis species, which are among the most common causative
agents of IE. The data also indicate that GspB, Hsa and SrpA
studied in the present work are representatives of many Sia-
binding SRR proteins. The results and methods from this work
should thus be broadly applicable.
Bacteria show multiple modes of binding to human
saliva, purified glycoproteins and related
glycoconjugates
Streptococci normally reside in the oral cavity, where they use
multiple adhesins for commensal interactions [33], and only a
subset of strains are known to become opportunistic pathogens in
the endovascular environment, causing diseases such as IE. We
thus wanted to probe the broader range of adhesins on DL1,
M99 and SK36, asking if they use the same adhesins in the oral
cavity for colonization and in the bloodstream. We used a dot
blot assay to assess bacterial binding to whole human saliva,
salivary ductal secretions, isolated and purified glycoproteins, and
related glycoconjugates. In addition, we examined whether
binding required divalent cations.
Under divalent cation-chelating conditions (+EDTA) (Fig-
ure 3A, see substrate info in Figure S5), wild type DL1 bound
saliva samples A1, A3, and A5, but not de-sialylated samples A2,
A4 and A6. Similarly, DL1 interacted with various sialylated
glycoproteins but showed much reduced or no binding to
corresponding desialylated glycoproteins. These included, for
example, salivary mucins MUC5B (B1) and MUC7 (B3). When
the adhesin-deficient strain DL1Dhsa was used under the same
conditions in the bacterial overlay, binding was not seen. For M99
and SK36, the Sia-dependent interactions were also absent when
corresponding adhesin-deficient strains were used (Figure S5).
These data show that the Siglec-like SRR adhesins are involved in
bacterium-saliva and various sialoglycoprotein interactions, and
confirm that they interact with their Sia-ligands in a Ca2+/Mg2+
independent manner [26].
In contrast, the binding profiles changed considerably in the
presence of Ca2+/Mg2+ (Figure 3B). Additional binding activities
that did not involve Sias were observed and those interactions
largely obscured the Sia-dependent patterns seen in EDTA. Most
conspicuously, DL1 bound to N-acetylgalactosamine (GalNAc)-
terminated structures (G5, K1, K3 and K4), and these interactions
were still present with the Hsa-deficient mutant. This fits previous
findings [34], indicating that lectin-like adhesins apart from the
Sia-binding ones are also expressed on such oral streptococci.
Similarly, M99 bound to terminal b-galactose (Gal) glycan
structures (I6, and K6), while SK36 also interacted with
GalNAc-terminated structures, as was seen with DL1 (G5, K1,
K3 and K4) (Figure S5).
Taken together, the data indicate that these bacteria express
additional adhesins beyond Sia-binding ones. These multiple
adhesins likely evolved to interact with salivary and oral mucosal
glycoproteins and/or other glyco-epitopes, e.g. the ones present in
Gal/GalNAc receptor polysaccharides on coaggregating bacterial
strains [35], which could be essential for their biofilm formation
and colonization in the oral cavity. Moreover, the asialoglycan-
binding adhesins require divalent cations for action, unlike the Sia-
binding SRR-adhesins.
Streptococcal strains primarily depend on Sia-binding
adhesins to hemagglutinate red blood cells in vitro
When oral streptococci enter the bloodstream, they encounter
a drastically different environment, with regard to terminal
glycan sequences available for adhesin binding. Unlike the case in
the oral cavity, terminal Gal and GalNAc residues are not
tolerated on plasma- or blood cell surface glycoconjugates, as they
are immediately recognized for clearance by receptors on
hepatocytes or macrophages [36,37]. Instead, the endovascular
system is an environment where numerous sialoglycans exist [28].
Thus, the Sia-binding SRR adhesins should theoretically become
Oral Streptococci Target Platelets in Fluid Human Whole Blood
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the more prominent determinants of glycan-mediated binding in
the bloodstream. To test this hypothesis we probed interactions of
DL1 and DL1Dhsa with human RBCs in traditional hemagglu-
tination assays, in the presence or absence of EDTA (Figure 3C–
3F). Hemagglutination was comparable under all conditions
when untreated RBCs were used (Figure 3C, all three rows), i.e.,
independent of divalent cations. Moreover, no hemagglutination
was observed with DL1Dhsa under any condition (Figure 3D, all
three rows). Thus, GalNAc- or Gal-binding adhesins do not
contribute significantly to bacterial hemagglutination, which is
predominantly mediated by Sia-recognition.
In contrast, when the RBCs were sialidase-treated and
underlying glycans were exposed, DL1 bound avidly to such
RBCs in the presence of Ca2+/Mg2+ (Figure 3E, third row).
Furthermore, this was independent of the Sia-binding adhesin Hsa
(Figure 3F, third row). These hemagglutination reactions were
most likely mediated by GalNAc- and/or Gal-binding adhesins
expressed on DL1, when their ligands on RBCs became exposed
by sialidase treatment, and in the presence of divalent cations.
Indeed, neither DL1 nor DL1Dhsa showed any hemagglutination
of sialidase-treated RBCs when Ca2+/Mg2+ were absent (Fig-
ure 3E and 3F, first two rows).
Taken together, the results fit the finding that normal RBCs are
primarily covered by sialoglycans without many exposed GalNAc
or Gal residues [38]. Although DL1 possesses both the Sia-binding
adhesin and other adhesins including other types of lectin-like
adhesins, the bacterium depends primarily on the former to bind
RBCs. In the oral cavity, where these streptococci normally reside,
they likely utilize many kinds of adhesins evolved for colonization
[34,39]. However, when they enter the blood stream, an
environment where Sias dominate the terminal glycome, they
become primarily dependent on their Sia-reactive SRR adhesins
to mediate binding.
Comparative binding of isogenic pairs of bacteria to
human blood components confirm the critical role of SRR
adhesins and host sialic acids
We then systematically compared binding of the three isogenic
pairs of strains to blood cells, including RBCs and platelets
(Figure 4A and 4B). Hemagglutination assays confirmed that the
sialic acid-mediated interactions of DL1, M99 and SK36 with
human RBCs were dependent on their respective SRR adhesins,
Hsa, GspB and SrpA (Figure 4A). An immobilized platelet
adhesion assay showed similar trends among the three strains
(Figure 4B). Notably, the SRR adhesin-deficient mutant strains
displayed residual binding to platelets, indicating that other
adhesins expressed on such strains could contribute to the
platelet-bacterial interactions. We also tested bacterial binding to
immobilized whole human plasma glycoproteins by dot blot
(Figure 4C). Both DL1 and M99 showed clear Sia- and Hsa-
dependent binding to whole plasma. In contrast, SK36 showed
minimal binding to whole plasma under the conditions tested.
A novel whole bacterium-whole blood flow cytometry
(WBWB-FC) assay shows that oral streptococci
preferentially adhere to platelets in intact human whole
blood
Although binding of the different strains to separate human
blood components has been studied by us and others, evaluation of
such binding in human whole blood has not been addressed to
date. However, the latter approach is most biomedically relevant.
Bacteria entering the bloodstream would encounter ,2 mM
concentration of competing sialoglycoproteins in the plasma [40]
and over 100-fold larger total RBC surface area than that of
platelets (average single RBC surface area: 2S = 26pr2 =
263.146(4 mm)2, and average RBC count: 4.40–6.006106/mL;
Figure 2. Phylogeny of SRR glycoprotein BRs from a representative number of S. sanguinis and S. gordonii strains, and glycan
binding to immobilized adhesin-BRs. (A) ClustalW2 was used for both the sequence alignment and the neighbor-joining tree reconstruction.
Corresponding SRR adhesin-BR sequence accession numbers are provided in Table S3. (B) PAA-supported sTa binds to both the Hsa-BR and BRs of
the four GspB-orthologues. (C) PAA-SLn only binds to Hsa-BR. (n = 6, SEM).
doi:10.1371/journal.ppat.1004540.g002
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average single platelet surface area: 2S= 26pr2 = 263.146
(1.5 mm)2, and average platelet count: 0.14–0.406106/mL). Thus
the question arises as to whether these bacteria can preferentially
detect platelets under such conditions.
To address this question we developed a novel whole
bacterium-whole blood flow cytometry (WBWB-FC) assay, in
which fluorochrome-labeled bacteria and antibodies were mixed
into fresh anti-coagulated human blood, allowed to interact for
short time, and then rapidly diluted before immediate analysis by
flow cytometry. Two distinct populations of cells were seen when
the mixture was analyzed by forward (FSC) and side scatter (SSC)
(Figure 5A, 5D, 5J and 5M). Erythrocytes were identified by the
expression of glycophorin A (CD235a) (Figure 5E), and platelets
by GPIIb (CD41a) (Figure 5F). Minimum non-specific interactions
were seen as a result of careful selection of antibodies and
optimization of assay conditions. Bacteria showed no interaction
with the antibodies used (Figure 5G–5I). When wild type DL1 was
added in whole human blood, it preferentially recognized platelets
as compared with RBCs (Figure 5K and 5L, note the percentage
values of Q2/Q1). When DL1Dhsa was used, the preferred
platelet-bacterial interaction was lost (Figure 5N, compare to 5K
and 5O). The M99 and SK36 isogenic pairs gave similar results,
albeit lower extent of preferential platelet binding by wild type
M99 or SK36 was observed compared to by DL1.
Figure 3. Bacterial binding to saliva and glycoconjugates, and bacterium-mediated hemagglutination. (A and B) Binding of DL1 vs.
DL1Dhsa against immobilized whole human saliva, salivary ductal secretions, isolated and purified glycoproteins and related glycoconjugates, was
tested by a dot blot assay. The binding was studied in the presence of EDTA (A) or divalent cations (B). (C–F) Bacterium-mediated hemagglutination
using human RBCs and two-fold serial diluted bacterial suspensions. (C and D) DL1- and DL1Dhsa-mediated hemagglutination using non-sialidase
treated (Ø) RBCs. (E and F) DL1- and DL1Dhsa-mediated hemagglutination using sialidase treated (S) RBCs.
doi:10.1371/journal.ppat.1004540.g003
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We next determined the effect of divalent cations on whole
bacterium-whole blood bindings (Figure 6A). Interactions were largely
comparable in either EDTA or heparin anti-coagulated blood,
indicating that divalent cations did not influence binding events much.
In addition, an anti-P-selectin antibody was used to monitor platelet
activation during the course of whole blood-bacterial binding
experiments. Minimum activation was observed, indicating that these
bacteria interacted with platelets in their resting state (Figure S6).
Thus, for the first time, we have demonstrated that the viridans
group streptococcal strains can utilize their Siglec-like domain-
containing SRR adhesins to preferentially bind platelets in the
setting of human whole blood, despite numerous potential binding
competitors, e.g., plasma- and other blood cell surface sialoglyco-
proteins. Divalent cations in whole blood also showed minimal
effect on these bacterial interactions with blood cells, supporting
the dominant roles of Sia-binding adhesins for streptococcal
recognitions in the blood stream.
Bacterial adhesin BR proteins preferentially recognize
platelets in whole blood similar to corresponding whole
bacteria
To pursue future studies in this area it would be important to know
if the recombinant adhesin-BR proteins can also preferentially detect
platelets in the setting of human whole blood. As a proof of concept,
we tested Hsa-BR. Notably, it indeed clearly displayed a strong
preference to bind human platelets compared to RBCs (Figure 6B).
Also, it increasingly adhered to platelets when more protein was used
(Figure 6D–6F and Figure S7). As a control, secondary antibody
alone did not distinguish platelets fromRBCs (Figure 6C). These data
indicate that sialic acid ligand density, accessibility, and/or particular
sialoglycan presentation [41] on platelets play an essential role in
mediating the preferred platelet-bacterial binding.
Adhesin BR proteins can block favored
bacterium-platelet interactions in human whole blood
Based on the above data, we further hypothesized the
recombinant adhesin-BR proteins would be capable of inhibiting
the preferred platelet-bacterial interaction in human whole blood.
We thus tested Hsa-BR in inhibiting DL1-platelet binding. It was
found that the favorable DL1-platelet interaction was gradually
inhibited by increasing concentrations of added soluble recombi-
nant Hsa-BR protein (Figure 7). In keeping with this blocking of
platelet-bacterial interactions, increasing numbers of un-bound
bacteria were detected with increasing amounts of recombinant
Hsa-BR added (Figure 7C–7E, quadrant 3). Furthermore, the
adhesin-blocking effect was verified by platelet adhesion assay
using washed and immobilized platelets (Figure S8).
Figure 4. Bacterial interactions with separated erythrocytes, platelets, and whole human plasma. (A) Wild type bacteria only
hemagglutinate non-sialidase treated RBCs. Mutant strains do not show any hemagglutination. Bars represent median values. (n = 3). (B) Bacterial
adhesion to fixed, immobilized platelets. (n = 6, SEM). (C) Whole plasma samples were immobilized on dot blot in three-fold serial dilutions starting
from the original concentration in whole blood. Each strain was tested to interact with either non-sialidase treated (Ø) or sialidase treated whole
plasma (S). *P,0.05, ***P,0.001.
doi:10.1371/journal.ppat.1004540.g004
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Discussion
The incidence of and mortality from IE has not reduced over
the past three decades, despite significant improvements seen in
most other diseases during the same period of time [4]. The
incidence of IE is about 1.4–12.7 per 100,000 person-years [1],
and mean in-hospital mortality is as high as 20% and one-year
mortality up to 40% [4]. Without treatment, IE is often lethal. In
short, IE remains an important medical and socioeconomic
burden to date.
Bacterial adhesins play critical roles in host-microbe interactions,
mediating host signaling events and affecting bacterial uptake or
invasion [42]. Sialic acid-binding adhesins of viridans group
streptococci are among the first identified lectin-like adhesins
[43,44]. This is not surprising considering the ubiquity of sialic acids
on host cell surfaces and in mucosal secretions, and their usual
occurrence at terminal positions of various glycoproteins and
glycolipids [25]. Notably, 70%–90% of streptococcal strains from a
collection of S. sanguinis, S. gordonii, and S. oralis species were
reported to express sialic acid-reactive adhesins, unlike the other
streptococcal species such as the S. anginosus [45]. This is in
intriguing coincidence with independent findings that S. sanguinis,
S. gordonii, and S. oralis are among the leading causative organisms
of streptococcal IE [46]. Taken together, the Sia-adhesin mecha-
nism we have elaborated in the current study might play a much
more prevalent role in the pathogenesis of IE than currently
recognized. Of course, such a mechanism may not be restricted to
SRR type adhesins that we emphasize in the present work.
On a broader scale, SRR glycoproteins constitute an important
family of conserved cell surface proteins associated with
Figure 5. Representative flow cytometry profiles showing preferential platelet-bacterial adherence in intact whole human blood.
(A–C) Whole blood (WB) in PBS. (D–F) Two antibodies, CD235a-FITC and CD41a-APC, were added to WB. (G–I) DL1-Cy3 incubated with CD235a-FITC
and CD41a-APC: (G) DL1-Cy3 also appears in Q4 in the FSC/SSC plot, the same as platelets. (J–L) DL1-Cy3, CD235a-FITC and CD41a-APC were added to
WB: (J) Platelets/bacteria are gated as R1 and RBCs/WBCs as R2. (K) Events from gate R1. (L) Events from gate R2. Bacteria preferentially recognize
platelets compared to RBCs. (M–O) DL1Dhsa-Cy3, CD235a-FITC and CD41a-APC were added to WB: (N) Events from gate R3, and DL1Dhsa-Cy3 bound
platelets are drastically reduced compared to DL1-Cy3 bound platelets. (O) Events from gate R4. Blood samples from multiple donors were tested and
consistent results were obtained.
doi:10.1371/journal.ppat.1004540.g005
Figure 6. Divalent cation effect on bacterial binding and preferential recognition of platelets over RBCs by Hsa-BR in whole blood.
(A) DL1 and DL1Dhsa binding to either platelets or RBCs were comparable in EDTA- or heparin-anticoagulated whole blood. Bar
values = 1006[number of bacterium-bound platelets (or RBCs)/total number of platelets (or RBCs)]. (n = 3, SEM). (B) Quantification and comparison
of Hsa-BR binding to platelets and RBCs in whole blood. Bar values = 1006[number of HsaBR-bound platelets (or RBCs)/total number of platelets (or
RBCs)]. (n = 6, SEM). (C) Q1 shows mainly RBCs, and Q4 platelets. Only 2u antibody, anti-GST-APC, alone was added in whole blood. (D–F) 6 to 96 pmol
of Hsa-BR was added to whole blood, followed by anti-GST-APC. ****P,0.0001.
doi:10.1371/journal.ppat.1004540.g006
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Gram-positive pathogenesis. Among the important questions
arising, it is imperative to achieve full characterization of cognate
ligands for these adhesins [16]. In this regard, glycan microarrays
serve as a valuable tool. It allows simultaneous screening of
hundreds of glycan-protein interactions in a high-throughput
manner and only requires minimal materials. For the first time, we
characterize in detail the glycan-binding spectra of a series of
serine-rich repeat adhesins of oral streptococci. This is a highly
conserved family of glycoproteins that contribute to virulence for a
broad range of Gram-positive pathogens [16]. The information
may help us to understand tissue and site tropism of the
streptococcal adhesion within the oral cavity and elsewhere.
Useful glycoanalytical probes are also identified. The bacterial
adhesin Hsa-BR fusion protein shows great promise in replacing
plant lectins MAL-I and MAL-II as a broad-range probe for a2-3-
linked sialic acids. For instance, to our knowledge, there was not a
good lectin for glycan microarray quality control to probe all a2-3-
linked sialic acids. Hsa-BR will thus prove useful in such efforts as
well as in other applications including cell and tissue staining. It is
also gratifying to have achieved successful whole bacterial binding
onto sialoglycan microarrays, which enables direct comparison of
glycan-binding properties between whole bacteria and their
corresponding adhesins. This approach not only confirms that
adhesin-BRs faithfully represent the Sia-binding properties of
corresponding whole organisms, but also demonstrates that the
Siglec-like domain-containing SRR adhesins are responsible for
the observed binding.
Whole bacteria bind defined sialoglycoproteins in a Sia- and
SRR adhesin-dependent manner as well. The evaluation of
divalent cation effects on adhesin binding also provides valuable
information for understanding differential contribution of bacterial
adhesins in different biological niches. In the oral cavity, where
free divalent cation concentrations in saliva usually exceed 1 mM
in healthy individuals [47], the multiple Ca2+/Mg2+-dependent
adhesins on different bacteria bind their receptors and obscure the
Ca2+/Mg2+-independent Sia-adhesin recognition events. In hu-
man blood, the normal plasma level of divalent cations typically
exceeds 2 mM [47]. However, the Ca2+/Mg2+-independent sialic
acid-reactive SRR-adhesins become dominant in recognition
events in the bloodstream.
Animal models of IE have been used for decades as tools for
examining this disease [48–50]. However, there are general
concerns about merely relying on animal models to infer human
relevance [51,52]. For example, studies of sepsis in mice versus
humans have shown markedly different outcomes, which were
corroborated by markedly different gene expression profiles [53].
Also, marked differences among human and animal glycomes exist
[54,55]. In this regard, our whole bacterium-whole human blood
evaluation is highly complementary to animal studies and most
relevant to the native human conditions.
Compared to conventional in vitro studies, several advantages
are evident with the WBWB-FC assays developed here. For
example, these assays faithfully present all components involved in
real human conditions (other than endothelium), a feature
incomparable by any other experimental system. Minimal sample
manipulation is required. No RBC lysis, wash or separation steps
are required, rendering the assays fast and facile. Minimizing
manipulations of whole blood not only avoids loss of cells, but also
ensures minimal alterations to blood cell phenotypes so that results
obtained reflect more accurately the in vivo situations. In addition,
Figure 7. Blocking of DL1-platelet binding by Hsa-BR in whole human blood. (A) Representative FSC/SSC plot showing whole blood with
added DL1-Cy3. Platelets and bacteria are gated as R1. (B–E) are gated from R1: (B) Whole blood with DL1-Cy3 and CD41a-APC. Non-DL1-bound
platelets appear in Q1 and DL1-bound in Q2, while free DL1-Cy3 in Q3. (C–E) Whole blood with different concentrations of Hsa-BR added first,
followed by DL1-Cy3 and CD41a-APC. Increasing amount of Hsa-BR results in decreasing count of DL1-bound platelets (Q2 percentages) and
increasing numbers of free bacteria (Q3 percentages). (F) Quantification of Hsa-BR blocking of DL1 binding to platelets in whole blood. The
percentage values of DL1-bound platelets were normalized, with the highest single value being 100%. (n = 6, SEM). *P,0.05, ***P,0.001.
doi:10.1371/journal.ppat.1004540.g007
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the method allows routine analysis using whole blood volumes of
merely 10 mL per tube, a considerable reduction compared to
standard methods. Finally, the assay is simple, sensitive, and
reproducible.
The WBWB-FC assays in the present work provide the first
definitive evidence that these oral streptococci can preferentially
recognize platelets in intact human whole blood, despite the
numerous alternative sialoglycoprotein ligands in plasma and on
other blood cells. This preferential platelet-bacterial interaction
readily occurs in the fluid whole blood, and may play a significant
role in the pathogenesis of IE. Platelets may thus act as
discriminative vehicles to deliver particular Sia-binding bacteria
to damaged valvular endocardium. In other words, these bacteria
inadvertently hitch a ride on circulating platelets and the platelets
act as Trojan horse carriers of oral streptococci to the site of
damaged endocardium.
Aside from novel mechanistic insights, the present work also
provides valuable information from a biomedical point of view.
Recent guidelines on the prevention of infective endocarditis have
greatly reduced the indications for antimicrobial prophylaxis, in
part because of concerns that the risks of these agents may
outweigh the benefits [56,57]. Targeting virulence has been
proposed as a promising means to reduce antibiotic use and
circumvent increasing antibiotic resistance [58,59]. The various
sialoglycan ligands identified by our glycan microarray screening
might be used to produce glycan-based inhibitors against bacterial
adhesion, and the rigorously verified Sia-binding adhesin-BR
proteins could be potentially developed into prophylactic drugs to
block the host target which the opportunistic pathogens exploit to
cause IE. As a proof of concept, we have shown that Hsa-BR can
successfully block corresponding DL1 binding to platelets in intact
human whole blood. Alternatively, these adhesin-BR proteins
might be explored as vaccines to boost immunity and generate
blocking antibodies against such streptococcal infections. More-
over, the WBWB-FC assay provides a novel method for
determination of susceptibility of culprit pathogens to potential
virulence inhibitors.
Meanwhile, our data provide an explanation why it is that
among numerous microbes that can gain access to the blood-
stream, certain viridans group streptococci have a selective
advantage in colonizing damaged cardiac valves. Unlike the
common situation where pathogens systematically evolve virulence
by optimizing binding to specific host targets, this is a case wherein
sialoglycan-binding properties that aid normal oral commensalism
inadvertently predispose these bacteria to become serendipitous,
yet highly specific pathogens.
Materials and Methods
Ethics statement
All research involving human participants have been approved
by our Institutional Review Board (IRB) or an equivalent
committee. Each healthy donor was individually informed and
gave his/her written consent for using the collected samples in a
scientific study. Collection and use of blood samples included in
this study was approved by the Human Research Protections
Program (HRPP, #080677X), and saliva samples by the Health
Sciences Institutional Review Board (HSIRB, #ORB0511008E).
Antibodies and other reagents
Allophycocyanine (APC)-conjugated CD41a, fluorescein iso-
thiocyanate (FITC)-conjugated CD62P, and control IgG1-FITC
were obtained from Becton Dickinson (San Diego, CA, USA).
FITC-conjugated CD235a (Glycophorin A) was obtained from
eBioscience (San Diego, CA, USA). Anti-GST SureLight APC was
obtained from Columbia Biosciences (Maryland, MD, USA).
Alexa Fluor 555-conjugated goat anti-rabbit IgG (H+L) and
Glutathione S-transferase rabbit IgG antibody fraction were
obtained from Molecular Probes (San Diego, CA, USA). Anti-
MBP antiserum was obtained from New England Biolabs (San
Diego, CA, USA). All chemicals were obtained from Sigma-
Aldrich (St. Louis, MO, USA), unless otherwise stated.
Bacterial strains and plasmids
The bacterial strains and plasmids used in this study are listed in
Table S1. Streptococci were grown in Brain Heart Infusion
(Becton Dickenson) at 37uC in a 5% CO2 environment for 18 h
with no agitation. Antibiotic selection was not required for strains
carrying chromosomally integrated plasmids or DNA fragments.
Strain PS1070 secretes a truncated form of GspB into the culture
medium, but has no detectable GspB associated with the cell wall.
Construction of BR expression plasmids
The gspB BR was amplified from chromosomal DNA of S.
gordonii strains 72-40 and PS478 using primers RGspBgst2 and
RGspBgst3, and then cloned in pGEX3X (GE Healthcare) as
described for cloning of the BR of strain M99 [60]. The BR coding
region of S. gordonii strain G9B was similarly amplified from
chromosomal DNA using the forward primer 59AAGGGGA-
TCCCAGAAGCTTCTAGTCAGACAGGCCGG and reverse
primer 59GTGCCTTGCAGAATTCGAAGTACTTCCTTCT-
CTTGT (BamHI and EcoRI sites are underlined), and then
cloned into pGEX3X. Engineered versions of the HsaBR and
SrpABR coding regions, with codons optimized for expression in
E. coli, were subcloned from plasmids pSV278-HsaBR and
pSV278-SrpABR, respectively, into pGEX5X.
Expression and purification of fusion proteins
Cultures of E. coli strain BL21 carrying the pGEX expression
plasmids were grown in LB with 50 mg/mL carbenicillin until on
OD600 of approximately 0.6. Cultures were placed on ice for
20 min, and the expression of GST fusion proteins was induced by
the addition of IPTG to a final concentration of 0.1 mM. Cultures
were incubated for 16 h at 18uC. Cells were harvested by
centrifugation and lysed by sonication, and the GST fusion
proteins were purified using Glutathione Sepharose 4B (GE
Healthcare) according to the manufacturer’s instructions. The
eluted proteins were exchanged into DPBS and stored at 280uC.
Fluorescence-labeling of bacteria
Labeling was performed as previously described [61], except
that cyanine 3 (Cy3) mono-reactive NHS ester (GE Healthcare)
was chosen as the fluorescent label. Cy3-labeled bacteria were
washed and resuspended in PBS before use in bacterial overlay,
sialoglycan microarray and whole blood binding assays.
Sialoglycan microarray screening of adhesin-BR proteins
and labeled whole bacteria
Glycan microarrays were fabricated using epoxide-derivatized
slides as previously described [29]. Printed glycan microarray
slides were blocked by ethanolamine, washed and dried, and then
fitted in a multi-well microarray hybridization cassette (AH
C4X8S, ArrayIt, Sunnyvale, CA, USA) to divide into 8 subarrays.
The subarrays were blocked with Ovalbumin (1% w/v) in PBS
(pH 7.4) for 1 h at RT, with gentle shaking. Subsequently, the
blocking solution was removed by aspiration and diluted adhesin-
BR samples were added to each subarray. After incubating the
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proteins for 2 h at RT with gentling shaking, the slides were
extensively washed to remove non-specifically bound proteins.
Anti-GST rabbit IgG fraction was added to the subarrays,
incubated at RT for 1 h, and washed. Anti-MBP antiserum was
used when MBP-tagged Hsa-BR was tested. Fluorescently labeled
antibody (Alexa Fluor 555-labeled goat anti-rabbit IgG (H+L),
Molecular Probes) was then applied and incubated for 1 h.
Following final washes and drying, the developed sialoglycan
microarray slides were subjected to scanning by a Genepix 4000B
microarray scanner (Molecular Devices Corp., Union City, CA,
USA) immediately. For Cy3-labeled whole bacteria, the glycan
glass slides were blocked with Ovalbumin (3% w/v) in PBS
(pH 7.4) for 1 h at RT, bacteria were subsequently added to the
arrays and allowed to interact with the glycans at RT for 2 h. After
extensive washing and drying, the bacterium-bound slides were
scanned. Data analysis was done using the Genepix Pro 7.0
analysis software (Molecular Devices Corp., Union City, CA). All
adhesin-BR fusion proteins and bacterial strains were tested and
compared at various concentrations on the arrays. The bacterium-
bound glass slides were also imaged by a Keyence microscope
(BIOREVO, BZ-9000, Keyence USA).
Identification of additional Siglec-like BRs
Homologues of the Siglec-like BRs were identified by BLAST
search of databases using the GspB signal peptide (residues 1 to
90), a highly conserved region of the S. gordonii and S. sanguinis
SRR glycoproteins.
Glycan binding to immobilized BR fusion proteins
The binding assay was performed following previously reported
protocol [26]. GST-BR fusion proteins were diluted to 0.5 mM in
DPBS, and 50 mL applied to microtiter wells. Plates were
incubated for 18 h at 4uC, unbound protein was removed by
aspiration, and the wells were rinsed three times with DPBS.
Multivalent biotinylated carbohydrates (GlycoTech Corporation)
were diluted to the indicated concentrations in DPBS containing
16Blocking Reagent (Roche), 50 mL was added to each well, and
the plate was incubated for 3 h at RT with vigorous rocking.
Unbound biotinylated carbohydrates were removed by aspiration,
and wells were washed three times with 100 mL DPBS. Fifty
microliters of streptavidin-conjugated horseradish peroxidase
(0.1 mg per mL in DPBS) was added to each well and the plate
was incubated for 1 h at RT. The wells were washed twice with
100 mL DPBS, and then 200 mL of a solution of 0.4 mg OPD per
mL phosphate-citrate buffer (Sigma) was added to each well. After
approximately 15 min, the absorbance at 450 nm was measured.
Dot blot preparations
Glycoarray dot blots for bacterial overlay were prepared by
immobilizing human salivary samples, naturally occurring glyco-
conjugates (Table S4) and neoglycoconjugates (Table S5) as dots
containing 1 mg of protein on nitrocellulose (0.45 mm pore size,
Whatman Protran BA 85, Fisher Scientific). The dot blots for
examining streptococcal binding to whole plasma were prepared
by spotting three-fold serial dilutions of human whole plasma from
their original concentrations (,68 mg/mL) as dots on nitrocellu-
lose. Samples were collected as previously described [62], except
that here un-stimulated WS samples were then spun at 12,0006g
for 15 min at 4uC to remove debris. The resultant clear
supernatant was transferred into a separate polypropylene
microtube and stored at 280uC until further use. Samples treated
with sialidase from Clostridium perfringens (Type X, Sigma-
Aldrich) and Arthrobacter ureafaciens (ProZyme, Hayward, CA) at
a final concentration of 0.05 U/mL at 37uC for 30 min were also
included in the dot blots where indicated.
Bacterial overlay
The overlay method was performed as previously described
[61]. In brief, blots were blocked in Tris-buffered saline (0.15 M
NaCl, 20 mM Tris HCl and 0.1% NaN3) containing 5% BSA
(TBS-BSA) for 2 h and then overlaid with labeled bacteria
suspended in TBS-BSA (108 bacteria per mL) for 2 h at 4uC in the
dark. Next, the blots were washed four times at 4uC for 5 min on a
rotary shaker with Tris-buffered saline (0.15 M NaCl, 20 mM Tris
HCl and 0.1% NaN3) containing 0.05% Tween-20 and dried on
gel blot paper (GB003, Whatman). Fluorescence signals of
adherent bacteria were detected by a fluorescence scanner
(TYPHOON 9400 imaging system, GE Healthcare). For condi-
tions where the overlay was done in the presence of divalent
cations, 1 mM CaCl2 and 1 mM MgCl2 were included in all
buffers; while for conditions where the overlay was done in the
absence of divalent cations, 5 mM EDTA was included.
Bacterial-mediated hemagglutination
Blood was collected in Vacutainers (Becton Dickenson)
containing 3.2% sodium citrate as anticoagulant. Erythrocytes
(RBC) were washed and resusupended in PBS containing 2 mg/
mL bovine serum albumin (Sigma-Aldrich, St. Louis, MO) (PBS-
BSA) to a final concentration of 10% (v/v). For the removal of
sialic acids, RBCs were treated for 1 h at 37uC with sialidase from
Clostridium perfringens (Type X, Sigma-Aldrich) and Arthrobac-
ter ureafaciens (ProZyme, Hayward, CA) at final concentration of
0.05 U/mL in PBS. Thereafter, ,16106 washed RBCs were used
in each well, with two-fold serial dilutions of each bacteria
suspension starting from ,36108 bacteria per well, in round-
bottom wells of a 96-well microtiter plate (Costar, Corning
Incorporated, Corning, NY). The endpoints of titrations were
determined after overnight incubation at 4uC. Images of
hemagglutination were taken with a digital camera (Canon EOS
50D).
Platelet adherence assay
Bacterial binding to immobilized human platelets was assessed
as described [13]. In brief, bacterial strains were grown for 18 h,
washed twice with DPBS, sonicated briefly to disrupt aggregated
cells, and then diluted to approximately 16107 bacteria per mL.
Fifty microliters of the bacterial suspensions were then applied to
microtiter plate wells containing platelet monolayers (,66106
platelets) that had been treated 1 h at RT with 100 mL of a
blocking solution (16 Blocking Reagent [Roche]) to reduce non-
specific adherence. In the case of adhesin-blocking experiment,
different concentrations of Hsa-BR were added and incubated for
1 h with the platelet monolayers, prior to the addition of DL1.
The plates containing bacteria and platelets were incubated at RT
for 3 h with vigorous rocking. Unbound bacteria were then
removed by aspiration and washing with DPBS, and the platelet-
bound bacteria were released by trypsinization. The number of
input and bound organisms was determined by plating serial
dilutions of the bacterial suspensions on sheep blood agar, and
binding was expressed as the percent of the input bacteria that
bound to the platelet monolayers.
Whole blood flow cytometry assays
Immunolabeling was performed immediately after blood draw.
Fresh whole blood was mixed with Cy3-labeled bacteria in
different ratios and the mixtures were incubated at room
Oral Streptococci Target Platelets in Fluid Human Whole Blood
PLOS Pathogens | www.plospathogens.org 12 December 2014 | Volume 10 | Issue 12 | e1004540
temperature for 0.5 h. Aliquots of the mixtures (10 mL) were
added to 5 mL polystyrene round bottom tubes (BD Falcon),
followed by adding anti-CD41a-APC and/or anti-CD235a-FITC.
After mixing gently, the mixtures were incubated at room
temperature for another 0.5 h, and then diluted by PBS (without
Ca2+/Mg2+) to 1 mL total volume for immediate analysis using a
FACS Calibur flow cytometer (BD Biosciences). For platelet
activation analysis, Cy3-labeled bacteria, anti-CD41a-APC, anti-
CD62P-FITC and IgG1-FITC control antibody were used. For
adhesin-BR binding, different amounts (6 pmol, 24 pmol, and
96 pmol) of GST-HsaBR were used together with anti-GST-APC.
In adhesin inhibition of whole bacterial binding studies, Hsa-BR
was added to whole blood samples and the mixtures were
incubated at room temperature for 0.5 h before Cy3-labeled
bacteria and anti-CD41a-APC were added. The resulting
mixtures were incubated at room temperature for another 0.5 h
before flow cytometric analysis. All results are expressed as
percentage of positive cells, either bacterium-bound or adhesin-
bound.
Statistical analysis
Statistical analyses were performed with GraphPad Prism 6.0
software. Bacterial adhesion to immobilized platelets was statisti-
cally analyzed using paired t test, bacterial and Hsa-BR binding in
whole human blood using 2way ANOVA, and Hsa-BR blocking
of DL1 binding in whole blood using 1way ANOVA. P values ,
0.05 were considered statistically significant.
Supporting Information
Figure S1 Sialoglycan microarray analysis of binding
specificity of MBP-tagged Hsa-BR fusion protein. The
MBP-tagged Hsa-BR show identical Sia-binding specificity as
GST-tagged Hsa-BR. (n = 4, SD).
(TIF)
Figure S2 Imaging of whole bacterial binding on the
slide sialoglycan microarrays. (A) DL1 binding to the
sialoglycan microarrays scanned by a Genepix 4000B microarray
scanner and visualized using the Genepix Pro 7.0 analysis
software. Specific whole bacterial bindings to a2-3-linked Sias
#1, 2, and 7-16 are shown. Glycans #3-6, 17, and 18 which are
a2-6-linked Sias do not show any binding to DL1. Each glycan
was printed on the glass slide in quadruplet. (B and C) Images of
different magnifications obtained by a high-resolution Keyence
microscope, showing high signal-to-noise ratio whole bacterial
binding on the glass slide glycan microarrays.
(TIF)
Figure S3 Amino acid sequence alignment using Clus-
talW2. The BR sequences of the four GspB orthologues were
analyzed by ClustalW2. They differ from each other by only a few
amino acid residues.
(TIF)
Figure S4 Sialoglycan microarray analysis of binding
specificities of GST-tagged GspB72-40BR, GspBG9BBR,
and GspBPS478BR. (A) Binding of GspB72-40BR. (B) Binding of
GspBG9BBR. (C) Binding of GspBPS478BR. (n = 4, SD).
(TIF)
Figure S5 Overall comparison of bacterial binding to
human saliva, purified glycoproteins and related glyco-
conjugates by dot blot. Binding of DL1 vs. DL1Dhsa, M99 vs.
M99DgspB, SK36 vs. SK36DsrpA are compared, in the presence
or absence of divalent cations.
(TIF)
Figure S6 Evaluation of platelet activation in whole
human blood in the presence of bacteria. Platelets were
gated and examined for activation, as indicated by CD62P
expression. RBCs were assessed as an internal negative control
from the same whole blood samples.
(TIF)
Figure S7 Histogram of different concentrations of Hsa-
BR binding to platelets in whole blood.
(TIF)
Figure S8 Hsa-BR inhibition of DL1 binding to washed
and immobilized platelet monolayer. Different concentra-
tions of Hsa-BR proteins were tested. (n = 3, SEM).
(TIF)
Table S1 Strains and plasmids employed in the study
[63–66].
(DOCX)
Table S2 Diversity of the sialoglycan library used in the
microarrays.
(DOCX)
Table S3 Accession numbers of the BR sequences
employed in the phylogenetic analysis.
(DOCX)
Table S4 Naturally occurring glycoconjugates used in
this study [67,68].
(DOCX)
Table S5 Neoglycoproteins used in this study.
(DOCX)
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